Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|11|1617-1619

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.11, 2014-06, pp. : 1617-1619

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neoadjuvant use of ipilimumab in locally advanced melanoma

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 112, Iss. 8, 2015-12 ,pp. : 841-843

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment patterns and outcomes in patients with advanced melanoma in France

By Bedane Christophe   Leccia Marie-Thérèse   Sassolas Bruno   Bregman Bruno   Lebbé Céleste  

Current Medical Research and Opinion, Vol. 29, Iss. 10, 2013-10 ,pp. : 1297-1305

Informa Healthcare

Access to resources Recommend Favorite

Is Removal of the Primary Tumor Beneficial in Breast Cancer with Synchronous Metastases? – There May Be More than One Answer

By  

Oncology Research and Treatment, Vol. 34, Iss. 11, 2011-10 ,pp. : 581-582

Karger

Access to resources Recommend Favorite

Histological evaluation of a “residual” metastasis after ipilimumab therapy in a patient with advanced melanoma

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 9, 2015-09 ,pp. : 927-928

John Wiley & Sons Inc

Access to resources Recommend Favorite

BRAF in early stage melanoma: rationale for testing and treatment?

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 173, Iss. 1, 2015-07 ,pp. : 9-10

John Wiley & Sons Inc

Access to resources Recommend Favorite